Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events.

No definition available.

Name:	apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryAndCommercialMilestoneEvents
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events.

+ References

No definition available.

+ Details

Name:	apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryDevelopmentAndCommercialMilestoneEvents
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Annual license maintenance fees.

+ References

No definition available.

+ Details

Name:	apls_AnnualLicenseMaintenanceFees
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative arrangement, maximum extendable term of agreement.

+ References

No definition available.

+ Details

Name:	apls_CollaborativeArrangementMaximumExtendableTermOfAgreement
Namespace Prefix:	apls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement, number of research programs.

+ References

No definition available.

+ Details

Name:	apls_CollaborativeArrangementNumberOfResearchPrograms
Namespace Prefix:	apls_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement, term of agreement.

+ References

No definition available.

+ Details

Name:	apls_CollaborativeArrangementTermOfAgreement
Namespace Prefix:	apls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative arrangement, up-front payment in next twelve months.

+ References

No definition available.

+ Details

Name:	apls_CollaborativeArrangementUpFrontPaymentInNextTwelveMonths
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative arrangement upfront non-refundable amount payable.

+ References

No definition available.

+ Details

Name:	apls_CollaborativeArrangementUpfrontNonRefundableAmountPayable
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contra research and development expense.

+ References

No definition available.

+ Details

Name:	apls_ContraResearchAndDevelopmentExpense
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract research and development current.

+ References

No definition available.

+ Details

Name:	apls_ContractResearchAndDevelopmentCurrent
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract research and development other assets.

+ References

No definition available.

+ Details

Name:	apls_ContractResearchAndDevelopmentOtherAssets
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract research and development other current assets.

+ References

No definition available.

+ Details

Name:	apls_ContractResearchAndDevelopmentOtherCurrentAssets
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract research and development receivable.

+ References

No definition available.

+ Details

Name:	apls_ContractResearchAndDevelopmentReceivable
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract research and development reimbursement commitment.

+ References

No definition available.

+ Details

Name:	apls_ContractResearchAndDevelopmentReimbursementCommitment
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development cost reimbursement.

+ References

No definition available.

+ Details

Name:	apls_DevelopmentCostReimbursement
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development cost reimbursement received.

+ References

No definition available.

+ Details

Name:	apls_DevelopmentCostReimbursementReceived
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestone achievement.

+ References

No definition available.

+ Details

Name:	apls_DevelopmentMilestoneAchievement
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment received for achievement of regulatory development milestone.

+ References

No definition available.

+ Details

Name:	apls_MilestonePaymentReceivedForAchievementOfRegulatoryDevelopmentMilestone
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

non-refundable upfront payment.

+ References

No definition available.

+ Details

Name:	apls_NonRefundableUpfrontPayment
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of licensed products.

+ References

No definition available.

+ Details

Name:	apls_NumberOfLicensedProducts
Namespace Prefix:	apls_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds from contract research and development .

+ References

No definition available.

+ Details

Name:	apls_ProceedsFromContractResearchAndDevelopment
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Regulatory milestone payments based on achievement.

+ References

No definition available.

+ Details

Name:	apls_RegulatoryMilestonePaymentsBasedOnAchievement
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalties entitled to receive after first commercial sale of applicable licensed product period.

+ References

No definition available.

+ Details

Name:	apls_RoyaltiesEntitledToReceiveAfterFirstCommercialSaleOfApplicableLicensedProductPeriod
Namespace Prefix:	apls_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Sales milestone payments based on achievement of annual sales milestones.

+ References

No definition available.

+ Details

Name:	apls_SalesMilestonePaymentsBasedOnAchievementOfAnnualSalesMilestones
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sublicense fee owed.

+ References

No definition available.

+ Details

Name:	apls_SublicenseFeeOwed
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	apls_UpfrontPayment
Namespace Prefix:	apls_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=apls_EmpaveliPegcetacoplanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=apls_SyfovreMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=apls_SwedishOrphanBiovitrumABPublMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=apls_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=apls_UniversityOfPennsylvaniaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=apls_TwoThousandTenLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=apls_SobiAgreementAndAnotherLicensingTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=apls_ResearchCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=apls_BeamTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Detail) $ in Thousands			1 Months Ended								3 Months Ended		12 Months Ended
	Nov. 30, 2020 USD ($)	Oct. 27, 2020 USD ($)	Apr. 30, 2023 USD ($)	Jan. 31, 2023 USD ($)	Jun. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Jan. 31, 2022 USD ($)	Aug. 31, 2021 USD ($)	Jun. 30, 2021 Program	Jan. 31, 2021 USD ($)	Mar. 31, 2023 USD ($) License	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Jul. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											$ 44,846	$ 14,381
EMPAVELI [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											20,440	12,109
SYFOVRE [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											18,360
Subsequent Event [Member] \| SYFOVRE [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments			$ 2,300
Swedish Orphan Biovitrum AB (Publ) [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development cost reimbursement		$ 80,000
Non-refundable Upfront Payment		250,000
Collaboration and License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development cost reimbursement													$ 80,000
Contract research and development expense											$ 80,000
Collaboration and License Agreement [Member] \| License [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment													$ 250,000
Collaboration and License Agreement [Member] \| Swedish Orphan Biovitrum AB (Publ) [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 250,000
Milestone payment received for achievement of regulatory development milestone						$ 50,000
Development cost reimbursement										$ 80,000
Development cost reimbursement received							$ 20,000			25,000
Royalties entitled to receive after first commercial sale of applicable licensed product period											10 years
Royalty revenue											$ 1,600	0
Contract research and development reimbursement commitment		80,000
Contract research and development expense												$ 5,000
Contract research and development receivable														$ 35,000
Contract research and development current											15,000
Contract research and development receivable other current assets														20,000
Contract research and development receivable other assets														$ 15,000
Proceeds from contract research and development				$ 20,000
Collaboration and License Agreement [Member] \| Swedish Orphan Biovitrum AB (Publ) [Member] \| ASC Topic 808
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 250,000
Development cost reimbursement		80,000
Collaboration and License Agreement [Member] \| Swedish Orphan Biovitrum AB (Publ) [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events																$ 915,000
Collaboration and License Agreement [Member] \| Swedish Orphan Biovitrum AB (Publ) [Member] \| Maximum [Member] \| ASC Topic 808
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate milestone payments upon achievement of specified one-time regulatory and commercial milestone events		$ 915,000
University of Pennsylvania [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Annual maintenance fees											100
Development milestone achievement					$ 5,000			$ 1,000
University of Pennsylvania [Member] \| EMPAVELI [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments based on annual sales milestones				$ 1,000
University of Pennsylvania [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate milestones payments											3,200
Milestone payments based on annual sales milestones											5,000
2010 License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Annual maintenance fees											$ 100
Number of licensed products \| License											2
2010 License Agreement [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate milestones payments											$ 1,700
Milestone payments based on annual sales milestones											$ 2,500
Sobi Agreement and Another Licensing Transaction [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fee owed										$ 25,000
Research Collaboration Agreement [Member] \| Beam [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement term									5 years
Number of research programs \| Program									6
Up-front non-refundable payment															$ 50,000
Up-front payment on first anniversary of agreement on June 30, 2022					$ 25,000
Collaboration agreement maximum extendable term					2 years